|Bid||104.50 x 800|
|Ask||113.80 x 800|
|Day's Range||105.78 - 109.07|
|52 Week Range||101.42 - 142.50|
|Beta (3Y Monthly)||0.81|
|PE Ratio (TTM)||28.88|
|Earnings Date||Oct 21, 2019 - Oct 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||140.71|
Today we are going to look at Varian Medical Systems, Inc. (NYSE:VAR) to see whether it might be an attractive...
PALO ALTO, Calif., Aug. 21, 2019 /PRNewswire/ -- Varian (VAR) today announced that Phil Febbo, MD, chief medical officer (CMO) at Illumina has been appointed to the Varian Board of Directors, effective August 16, 2019. "We are proud to have Phil Febbo join the Varian Board," said R. Andrew Eckert, chairman of Varian's Board of Directors. "Phil has a strong background in both clinical and research work, as well as company strategy.
PALO ALTO, Calif. , Aug. 21, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has successfully completed its asset purchase of the Boston Scientific portfolio of drug-loadable microsphere and ...
PALO ALTO, Calif., Aug. 19, 2019 /PRNewswire/ -- Varian (VAR) today announced that its executive management team will be hosting an Investor Day on Friday, November 15, 2019 at The Plaza Hotel, Fifth Avenue at Central Park South, New York, NY 10019, from 8:00am to 1:00pm ET. Varian will outline its growth initiatives in radiation oncology, interventional oncology, and more broadly across cancer care driven by its 'Intelligent Cancer Care' approach, the next wave of progress in oncology that harnesses advanced technologies like artificial intelligence, machine learning, and data analytics to ensure coordination and connectivity at every point of care. 'Intelligent Cancer Care' puts the patient and provider at the center of our thinking to help realize our vision of a world without fear of cancer.
PALO ALTO, Calif., Aug. 8, 2019 /PRNewswire/ -- Varian (VAR) today announced that its executive staff will be meeting with analysts and investors at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Chicago on Monday, September 16, 2019 at 2:00 p.m. Central Time. To attend Varian's ASTRO investor meeting, please RSVP to Katie Glenn at email@example.com by August 23, 2019. For automatic e-mail alerts regarding Varian news and events, investors can subscribe on the company website: http://investors.varian.com/emailalerts.
I've been keeping an eye on Varian Medical Systems, Inc. (NYSE:VAR) because I'm attracted to its fundamentals. Looking...
PALO ALTO, Calif., Aug. 5, 2019 /PRNewswire/ -- Varian (VAR) today announced that the newly proposed tariffs by the U.S. on the remaining $300 billion of Chinese imports should have no material impact to the company. Last Thursday, the U.S. announced plans to impose a 10 percent tax on $300 billion in Chinese imports beginning September 1, 2019. Varian estimates these newly proposed tariffs should have an immaterial financial impact. At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 9,200 employees across 70 countries keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
PALO ALTO, Calif. , July 29, 2019 /PRNewswire/ -- Following a public competitive review process, Varian (NYSE: VAR) was selected to supply its Eclipse ™ treatment planning software and ARIA ® oncology ...
PALO ALTO, Calif. and STOCKHOLM, July 25, 2019 /PRNewswire/ -- Varian (VAR) announced that the Karolinska University Hospital Solna in Sweden is the first hospital in Scandinavia to deliver High Dose Rate (HDR) brachytherapy treatments using the new Bravos™ afterloader system. Bravos is an advanced integrated system designed to improve the patient and clinic experience by simplifying brachytherapy treatments and provide greater workflow efficiency. HDR brachytherapy involves delivering radiotherapy by temporarily placing a small radioactive source directly into the tumor or other targeted area.
PALO ALTO, Calif. , July 24, 2019 /PRNewswire/ -- Third Quarter 2019 Summary Oncology Systems gross orders grew 2% in dollars, or 4% in constant currency; Trailing twelve months gross orders grew 11% in ...
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
Probable revenue growth in APAC and EMEA regions and higher Oncology revenues are likely to aid Varian Medical (VAR) in Q3 earnings. However, contraction in margins might be a dampener.
In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.
Varian (VAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SVP, Finance & CFO of Varian Medical Systems Inc (30-Year Financial, Insider Trades) Gary E Jr Bischoping (insider trades) sold 56,232 shares of VAR on 07/11/2019 at an average price of $132.56 a share. Continue reading...
PALO ALTO, Calif. , July 11, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be showcasing systems and software from its cancer care portfolio, including the IDENTIFY ™ Guidance System, ...